Trial Outcomes & Findings for Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients (NCT NCT01056107)

NCT ID: NCT01056107

Last Updated: 2013-05-31

Results Overview

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

52 participants

Primary outcome timeframe

24 hours (Visit 3 = Day 1)

Results posted on

2013-05-31

Participant Flow

Subjects were recruited at the Mayo Clinic in Rochester, Minnesota.

52 subjects were enrolled, but 6 subjects were excluded because they did not meet eligibility criteria.

Participant milestones

Participant milestones
Measure
ROSE-010 30 Mcg
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Overall Study
STARTED
11
11
12
12
Overall Study
COMPLETED
11
10
9
12
Overall Study
NOT COMPLETED
0
1
3
0

Reasons for withdrawal

Reasons for withdrawal
Measure
ROSE-010 30 Mcg
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Overall Study
Withdrawal by Subject
0
1
3
0

Baseline Characteristics

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Total
n=46 Participants
Total of all reporting groups
Age Continuous
43.4 years
STANDARD_DEVIATION 6.0 • n=99 Participants
40.2 years
STANDARD_DEVIATION 11.7 • n=107 Participants
42.0 years
STANDARD_DEVIATION 11.9 • n=206 Participants
43.8 years
STANDARD_DEVIATION 8.0 • n=7 Participants
42.4 years
STANDARD_DEVIATION 9.5 • n=31 Participants
Sex: Female, Male
Female
11 Participants
n=99 Participants
11 Participants
n=107 Participants
12 Participants
n=206 Participants
12 Participants
n=7 Participants
46 Participants
n=31 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
0 Participants
n=31 Participants
Region of Enrollment
United States
11 participants
n=99 Participants
11 participants
n=107 Participants
12 participants
n=206 Participants
12 participants
n=7 Participants
46 participants
n=31 Participants
Body Mass Index (BMI)
27.2 kg/m^2
STANDARD_DEVIATION 3.8 • n=99 Participants
26.4 kg/m^2
STANDARD_DEVIATION 5.5 • n=107 Participants
26.4 kg/m^2
STANDARD_DEVIATION 4.8 • n=206 Participants
27.7 kg/m^2
STANDARD_DEVIATION 4.0 • n=7 Participants
26.9 kg/m^2
STANDARD_DEVIATION 4.5 • n=31 Participants
Stool frequency
0.7 Stools/day
STANDARD_DEVIATION 0.3 • n=99 Participants
1.0 Stools/day
STANDARD_DEVIATION 0.8 • n=107 Participants
0.8 Stools/day
STANDARD_DEVIATION 0.6 • n=206 Participants
0.7 Stools/day
STANDARD_DEVIATION 0.4 • n=7 Participants
0.8 Stools/day
STANDARD_DEVIATION 0.5 • n=31 Participants
Stool Consistency
2.8 units on a scale
STANDARD_DEVIATION 1.1 • n=99 Participants
3.0 units on a scale
STANDARD_DEVIATION 0.8 • n=107 Participants
2.8 units on a scale
STANDARD_DEVIATION 1.8 • n=206 Participants
2.4 units on a scale
STANDARD_DEVIATION 0.9 • n=7 Participants
2.7 units on a scale
STANDARD_DEVIATION 1.2 • n=31 Participants

PRIMARY outcome

Timeframe: 24 hours (Visit 3 = Day 1)

Population: Intent-to-treat

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Colonic Transit, Colonic Geometric Center at 24 Hours
2.39 units on a scale
Standard Error 0.22
2.37 units on a scale
Standard Error 0.41
2.02 units on a scale
Standard Error 0.23
1.76 units on a scale
Standard Error 0.14

PRIMARY outcome

Timeframe: approximately 1 hour after 99mTC injection, approximately 30 min after liquid meal (Visit 5 = approximately 2-10 days after Visit 4)

Population: Intent-to-treat

A noninvasive SPECT method was used to measure gastric volume during fasting and 32 min after a liquid nutritional supplement meal. Subjects reported to the clinic after an overnight fast. 99mTC was giving by an intravenous injection in the forearm. The first fasting scan was obtained, and the study medication was given s.c. After 10 min, a 2nd fasting post medication scan was obtained, and the meal consumed; then two serial postprandial scans were obtained. Each scan required 9-12 min. Tomographic images of the gastric wall were obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body. This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content. For this outcome measure, the scans for the "fasting volume" and 2 "postprandial volumes" were used. The 2 postprandial (PP) volumes were averaged. Change was calculated as (PP - Fasting = gastric accommodation).

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging (Gastric Accommodation)
532.2 mL
Standard Error 36.6
575.6 mL
Standard Error 19.4
515.2 mL
Standard Error 52.5
532.8 mL
Standard Error 22.8

PRIMARY outcome

Timeframe: approximately 2 hours after radiolabeled meal is ingested (Visit 2 = Day 0)

Population: Intent-to-treat

Half time (t1/2) of gastric emptying (GE) of solids is the time for half of the ingested solids or liquids to leave the stomach. The scintigraphy for GE t1/2 was done on Visit 2 (Day 0 of the study), the first day of scintigraphy.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Half Time (t1/2) of Gastric Emptying of Solids Measured by Scintigraphy (Gastric Transit)
151.8 minutes
Standard Error 10.4
172.6 minutes
Standard Error 7.1
210.7 minutes
Standard Error 8.6
136.9 minutes
Standard Error 7.2

SECONDARY outcome

Timeframe: 2 hours, 4 hours (Visit 2 = Day 0)

Population: Intent-to-treat

The gastric residual will be calculated as the proportion of isotope remaining in the stomach (at 2 and 4 hours).

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Gastric Residual at 2 and 4 Hours Measured by Scintigraphy
Gastric residual at 4 hours
0.14 proportion of isotope in the stomach
Standard Error 0.03
0.16 proportion of isotope in the stomach
Standard Error 0.03
0.30 proportion of isotope in the stomach
Standard Error 0.06
0.12 proportion of isotope in the stomach
Standard Error 0.03
Gastric Residual at 2 and 4 Hours Measured by Scintigraphy
Gastric residual at 2 hours
0.66 proportion of isotope in the stomach
Standard Error 0.42
0.76 proportion of isotope in the stomach
Standard Error 0.03
0.86 proportion of isotope in the stomach
Standard Error 0.03
0.59 proportion of isotope in the stomach
Standard Error 0.04

SECONDARY outcome

Timeframe: 4 hours (Visit 2 = Day 0)

Population: Intent-to-treat

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (Note: when there is no radio isotope in the colon (e.g., at 4 hours) the geometric center values are recorded as "zero," thus the mean values can be less than one.)

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Colonic Geometric Center at 4 h Measured by Scintigraphy
0.70 units on a scale
Standard Error 0.20
0.47 units on a scale
Standard Error 0.16
0.57 units on a scale
Standard Error 0.17
0.53 units on a scale
Standard Error 0.17

SECONDARY outcome

Timeframe: 6 hours (Visit 2 = Day 0)

Population: Intent-to-treat

Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Colonic Filling at 6 h Measured by Scintigraphy
47.6 percentage of meal
Standard Error 7.4
54.4 percentage of meal
Standard Error 7.8
48.0 percentage of meal
Standard Error 10.0
53.5 percentage of meal
Standard Error 4.8

SECONDARY outcome

Timeframe: 48 hours (Visit 4 = Day 2)

Population: Intent-to-treat

Ascending colon emptying half-time will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Ascending Colon Emptying Half-time (AC t1/2) Measured by Scintigraphy
14.5 hours
Standard Error 1.6
14.8 hours
Standard Error 3.7
17.1 hours
Standard Error 4.0
19.3 hours
Standard Error 3.2

SECONDARY outcome

Timeframe: 48 hours (Visit 4 = Day 2)

Population: Intent-to-treat

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Colonic Transit, Colonic Geometric Center at 48 h Measured by Scintigraphy, as Compared to Placebo.
3.69 units on a scale
Standard Error 0.23
3.79 units on a scale
Standard Error 0.33
3.36 units on a scale
Standard Error 0.37
2.67 units on a scale
Standard Error 0.26

SECONDARY outcome

Timeframe: screening visit (Visit 1), 34 days (Visit 6)

Population: Intent-to-treat

Stool frequency was self reported in a Bowel Pattern Diary. The bowel pattern diary was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Stool Frequency
0.75 Stools/day
Standard Error 0.09
1.13 Stools/day
Standard Error 0.17
0.88 Stools/day
Standard Error 0.15
0.70 Stools/day
Standard Error 0.05

SECONDARY outcome

Timeframe: 34 days (Visit 6)

Population: Intent-to-treat

The subjects rated their stool consistency using the 7-point Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. The Bristol stool form was part of the bowel pattern diary, which was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.

Outcome measures

Outcome measures
Measure
ROSE-010 30 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 Participants
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 Participants
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Stool Consistency Post Treatment
2.93 units on a scale
Standard Error 0.33
2.96 units on a scale
Standard Error 0.36
2.93 units on a scale
Standard Error 0.47
3.05 units on a scale
Standard Error 0.32

Adverse Events

ROSE-010 30 Mcg

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

ROSE-010 100 Mcg

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

ROSE-010 300 Mcg

Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
ROSE-010 30 Mcg
n=11 participants at risk
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 100 Mcg
n=11 participants at risk
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
ROSE-010 300 Mcg
n=12 participants at risk
A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Placebo
n=12 participants at risk
Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
Gastrointestinal disorders
Nausea
9.1%
1/11 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
72.7%
8/11 • Number of events 8 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
75.0%
9/12 • Number of events 9 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Gastrointestinal disorders
Vomiting
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
18.2%
2/11 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
41.7%
5/12 • Number of events 5 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
8.3%
1/12 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Gastrointestinal disorders
Dry heaving
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
16.7%
2/12 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Gastrointestinal disorders
Stomach ache
9.1%
1/11 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
18.2%
2/11 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
8.3%
1/12 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Gastrointestinal disorders
Abdominal cramp
9.1%
1/11 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
9.1%
1/11 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
8.3%
1/12 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
16.7%
2/12 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Gastrointestinal disorders
Flatulence
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
18.2%
2/11 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
16.7%
2/12 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Gastrointestinal disorders
Bloating
18.2%
2/11 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
18.2%
2/11 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
8.3%
1/12 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
General disorders
Headache
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
27.3%
3/11 • Number of events 3 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
33.3%
4/12 • Number of events 4 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
16.7%
2/12 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
General disorders
Drowsiness
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
9.1%
1/11 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
25.0%
3/12 • Number of events 3 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
General disorders
Lightheadedness
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
18.2%
2/11 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
8.3%
1/12 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
16.7%
2/12 • Number of events 2 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
Skin and subcutaneous tissue disorders
Injection site rash
9.1%
1/11 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/11 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
8.3%
1/12 • Number of events 1 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.
0.00%
0/12 • Subjects were assessed for adverse events at every study visit, approximately over 22 days.

Additional Information

Dr. Michael Camilleri

Mayo Clinic

Phone: 507-266-2305

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place